Canadian Nuclear Laboratories and TRIUMF, the country’s particle accelerator center, have successfully produced actinium-225—a rare isotope that can be used for novel cancer therapy treatments.

“Because BI-RADS 3 breast lesions have up to 2% likelihood of malignancy, it is imperative that optimal follow-up of BI-RADS 3 test results be addressed...," authors of the new study published in JACR wrote.

The researchers analyzed 39 consecutive patients with 44 pathologically confirmed cirrhotic nodules who first received a CEUS exam, followed by a traditional follow-up ultrasound every three or four months for their study.

A new startup—Hyperfine—and its visionary leader Jonathan Rothberg are creating a new, portable MRI machine they believe can revolutionize the way doctors think about the technology.

Exposure to radioiodine can lead to DNA damage in thyroid cells and other tissue, but new research suggests current radiation protection principles may not be sufficiently monitoring radiation exposure to nuclear medicine professionals.

Manufacturers, hospitals, physicians and patient advocates have put significant marketing resources—including millions of dollars—into selling 3D mammograms to women, despite little evidence the modality is better than traditional mammography.

Using the quiet protocol reduced noise levels and improved imaging success rates compared to conventional MRI, according to authors of a new study published in Academic Radiology.

“A better understanding of how age and comorbid conditions affect mammography use may help target specific populations and improve use of preventive care," wrote Cindy Yuan, MD, PhD, with the University of Chicago’s Department of Radiology, and colleagues.